|
|
Saos-2
|
|
|
J Fogh, G Trempe
|
|
Biosafety Level:
|
1
|
|
|
frozen
|
|
Medium & Serum:
|
See Propagation
|
|
|
adherent
|
|
|
Homo sapiens (human)
|
|
|
epithelial
|
|
|
Organ: bone
Disease: osteosarcoma
|
|
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
|
|
|
The cells are distributed for research purposes only. The Memorial Sloan-Kettering Cancer Center releases the line subject to the following: 1.) The cells or their products must not be distributed to third parties. Commercial interests are the exclusive property of Memorial Sloan-Kettering Cancer Center. 2.) Any proposed commercial use of these cells must first be negotiated with The Director, Office of Industrial Affairs, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; phone (212) 639-6181; FAX (212) 717-3439.
|
|
|
transfection host (Nucleofection technology from Lonza
Roche FuGENE® Transfection Reagents)
|
|
|
epidermal growth factor (EGF); transforming growth factor beta (type 1 and type 2)
|
|
|
No
|
|
|
Blood Type B, Rh+; HLA A2, A3, Bw16, Bw47
|
|
|
Amelogenin: X
CSF1PO: 10
D13S317: 12,13
D16S539: 12,13
D5S818: 12
D7S820: 8,10
THO1: 6,9
TPOX: 8
vWA: 18
|
|
|
The stemline chromosome number is hypotriploid with the modal number of 56 chromosomes per cell and the 2S component occurring at 13.2%. Over two-thirds of the chromosome complement consisted of structurally rearranged chromosomes., Most marker chromosomes had complex rearrangements. The origin of the segments composing these markers could not be identified. Of the identifiable markers, 6p+/q+, 7p+, 11p+, and 12p+ occasionally were present at 2 copies per cell., The Y chromosome was not detected in the QM stained preparation.
|
|
|
AK-1, 1
ES-D, 2
G6PD, B
GLO-I, 2
Me-2, 1
PGM1, 1-2
PGM3, 1-2
|
|
|
11 years
|
|
|
female
|
|
|
Caucasian
|
|
|
ATCC complete growth medium: The base medium for this cell line is ATCC-formulated McCoy's 5a Medium Modified , Catalog No. 30-2007. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 15%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
|
|
|
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended
Medium Renewal: 1 to 2 times per week
Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach.
Add fresh culture medium, aspirate and dispense into new culture flasks.
|
|
|
Culture medium, 95%; DMSO, 5%
|
|
|
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2007
recommended serum:ATCC 30-2020
|
|
|
21441: Banerjee C, et al. An AML-1 consensus sequence binds an osteoblast-specific complex and transcriptionally activates the osteoclacin gene. Proc. Natl. Acad. Sci. USA 93: 4968-4973, 1996. PubMed: 8643513
21869: . Human tumor cells in vitro. New York: Plenum Press; 1975.
22536: Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871
22539: Fogh J, et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59: 221-226, 1977. PubMed: 327080
23014: Takeuchi Y, et al. Relationship between actions of transforming growth factor (TGF)-beta and cell surface expression of its receptors in clonal osteoblastic cells. J. Cell. Physiol. 162: 315-321, 1995. PubMed: 7860639
23015: Zhang W, et al. EGF-mediated phosphorylation of extracellular signal-regulated kinases in osteoblastic cells. J. Cell. Physiol. 162: 348-358, 1995. PubMed: 7860643
23226: Pollack MS, et al. HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines. J. Natl. Cancer Inst. 66: 1003-1012, 1981. PubMed: 7017212
32279: Schar BK, et al. Simultaneous detection of all four alkaline phosphatase isoenzymes in human germ cell tumors using reverse transcription-PCR. Cancer Res. 57: 3841-3846, 1997. PubMed: 9288797
32462: Morris GF, et al. Transcriptional activation of the human proliferating-cell nuclear antigen promoter by p53. Proc. Natl. Acad. Sci. USA 93: 895-899, 1996. PubMed: 8570655
32556: Werner H, et al. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc. Natl. Acad. Sci. USA 93: 8318-8323, 1996. PubMed: 8710868
32900: Wang X, et al. Variabilin, a novel RGD-contining antagonist of glycoprotein IIb-IIIa and platelet aggregation inhibitor from the gard tick Dermacentor variabilis. J. Biol. Chem. 271: 17785-17790, 1996. PubMed: 8663513
33153: Karnieli E, et al. The IGF-1 receptor gene promoter is a molecular target for the Ewing's Sarcoma=Wilms' Tumor 1 fusion protein. J. Biol. Chem. 271: 19304-19309, 1996. PubMed: 8702614
|
|
